EZH2 inhibitor phosphate prodrug (Pfizer Global Research and Development)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NameEZH2 inhibitor phosphate prodrug (Pfizer Global Research and Development)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone-lysine N-methyltransferase EZH2 degraders
TargetsHistone-lysine N-methyltransferase EZH2
Therapy Area/IndicationsLymphoma, Large B-Cell, Diffuse
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Global Research and Development
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Global Research and Development
Inactive CompaniesN/A
Active IndicationsLymphoma, Large B-Cell, Diffuse
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A